Form 4 Filing for Alkermes plc

Craig C. Hopkinson, EVP R&D, Chief Medical Officer of Alkermes plc, reported a series of transactions on May 1, 2026. He exercised employee stock options for 5,000 ordinary shares at a price of $19.34 per share, acquiring these shares under a Rule 10b5-1 trading plan. Following this acquisition, he sold 9,000 ordinary shares in multiple transactions at a weighted average price of $33.3955 (ranging from $33.21 to $33.49), also under a Rule 10b5-1 trading plan. These sales were executed to cover the exercise cost of the options. After these transactions, Mr. Hopkinson directly owns 81,389 ordinary shares.